Founded in 2017, by scientists from China and the UK, Allife Medicine has been at the forefront of advancing healthcare, through universal, off-the-shelf, and innovative cell medicine and gene therapy. Operating globally in China, the UK, and Malaysia, we take pride in pioneering China's, first iPSC derived cell therapy clinical trial, marking a historic milestone in the field. Our team, comprising nearly two hundred experts, forty-five of whom hold PhD degrees, has been instrumental in, generating over one hundred patents, and publishing more than eighty research papers, in international peer-reviewed journals. Our product pipelines showcase Phase one products: ALF201 and ALF202 targeting Acute Ischemic Stroke and Peripheral Limb Ischemia. It has demonstrated a significant improvement in stroke prognosis, extending the treatment window and providing hope to, the 70% of patients who are ineligible for intravenous thrombolytic therapy.